ABSTRACT
With aging, there is a correlation between a decline in the body’s ability to maintain regular functioning and greater susceptibility to age-related diseases. Therapeutic interventions targeting the underlying biological changes of aging hold promise for preventing or delaying multiple age-related diseases. Metformin, a drug commonly used for diabetes treatment, has emerged as a potential gerotherapeutic agent due to its established safety record and preclinical and clinical data on its anti-aging effects. Glycosylation, one of the most common and complex co- and post-translational protein modifications, plays a crucial role in regulating protein function and has been linked to aging and various diseases. Changes in IgG glycosylation patterns have been observed with age, and these alterations may serve as valuable biomarkers for disease predisposition, diagnosis, treatment monitoring, and overall health assessment. In this study, we analyzed the IgG glycosylation patterns of individuals under treatment with metformin, testosterone, metformin plus testosterone and placebo, and investigated the longitudinal changes in glycosylation over time. We observed statistically significant differences in the IgG glycome composition between participants on testosterone therapy and placebo, with decreased agalactosylation and increased galactosylation and sialylation. However, metformin therapy did not result in statistically significant changes in glycosylation patterns. These findings contribute to our understanding of the impact of therapeutic interventions on IgG glycosylation and confirm the value of IgG glycosylation as a significant biomarker, capable of assessing biological age using the GlycanAge index and providing insight into overall health compared to chronological age.
Competing Interest Statement
G. L. is the founder and owner of Genos Ltd, a private research organization that specializes in high-throughput glycomic analysis and has several patents in this field. M.V., T.P., A.F.H., and F.V. are employees of Genos Ltd. Other authors declare no competing interests.
Clinical Trial
NCT02514629
Funding Statement
This work was supported by the European Structural and Investment Funds IRI CardioMetabolic grant. Equipment and products from Waters, New England Biolabs®, Inc., and Applied Biosystems, Inc. were used for this research. J.C.F-G is supported by an intensification research program (INT21/00078, ISCIII, Spain; co-funded by the Fondo Europeo de Desarrollo Regional-FEDER). The funding organizations played no role in the design of the study, review and interpretation of the data, or final approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Department of Endocrinology and Nutrition at the Virgen de la Victoria University Hospital (Malaga, Spain) review boards and the ethics committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations
- ACN
- acetonitrile;
- APTS
- 8-aminopyrene-1,3,6-trisulfonic acid trisodium salt;
- CGE-LIF
- capillary gel electrophoresis with laser-induced fluorescence;
- DNA
- Deoxyribonucleic acid;
- Fab
- fragment antigen-binding;
- Fc
- fragment crystallizable;
- GlcNAc
- N-Acetylglucosamine;
- HiDi
- formamide;
- HILIC-SPE
- hydrophilic interaction liquid chromatography solid-phase extraction;
- IgG
- immunoglobulin G;
- PBS
- Phosphate buffered saline;
- PNGase F
- Peptide N-glycosidase F;
- SDS
- Sodium Dodecyl Sulfate;
- TEA
- Triethylamine.
